iStock-992980718

How can my patients receive Lysodren®?

HRA Pharma Rare Diseases is committed to providing the highest level of pharmacy services through its relationship with AllianceRx Walgreens Pharmacy.

How to prescribe:

Call, fax or e-scribe your prescriptions to AllianceRx Walgreens Pharmacy.

Call: 1-800-320-2112
Fax: 1-866-889-1510
e-scribe: search AllianceRx Walgreen Pharmacy

AllianceRx Lysodren Prescription Form

How do I e-prescribe to AllianceRx Walgreens Pharmacy for specialty medicines?

To provide the best access possible, our central specialty pharmacies are located in key regions across the country. While some restrictions may apply, you can usually send the prescription to whichever location listed below is closest to your patient. The preferred site for Lysodren (mitotane) is the Pittsburgh central specialty location.
If you are unsure where to send a prescription to, please call us at 855-244-2555.

AllianceRx (Specialty) Walgreens Pharmacy – PENNSYLVANIA
Pittsburgh, PA
130 Enterprise Drive
Pittsburgh, PA 15275
Phone: 888-347-3416
Fax: 877-235-9807

image006

Hospital and Institutional orders

For hospital and institutional orders, contact  Direct Success, Inc. at
1-844-597-6373 or Distribution@DSuccess.com.

INDICATION AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING ON ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

READ MORE ⇧
LYSODREN® is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma. Warning/Adrenal crisis in the setting of shock or severe trauma: In patients taking LYSODREN®, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN® until recovery.

CNS Toxicity: CNS toxicity, including sedation, lethargy, and vertigo, occurs with LYSODREN® treatment. Mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity.

Adrenal Insufficiency: Treatment with LYSODREN® can cause adrenal insufficiency. Institute steroid replacement as clinically indicated.

Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement.

Embryo-Fetal Toxicity: LYSODREN® can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes, such as preterm births and early pregnancy loss, can occur in patients exposed to mitotane during pregnancy. Advise females of reproductive potential to use effective contraception during treatment with LYSODREN® and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

Ovarian Macrocysts in Premenopausal Women: Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving LYSODREN®. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described.

Lactation: Mitotane is excreted in human milk; however, the effect of LYSODREN® on the breastfed infant, or effect on milk production is unknown.

Because of the potential for serious adverse reactions in the breastfed infant, advise nursing women that breastfeeding is not recommended during treatment with LYSODREN® and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

Hepatic Impairment: Administer LYSODREN® with caution to patients with hepatic impairment.

Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash. LYSODREN® is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Please see Full Prescribing Information, including BOXED WARNING, for LYSODREN® (mitotane) tablets.

To report SUSPECTED ADVERSE REACTIONS, contact Direct Success Pharmacy, Inc. at 1-844-LYSODREN (1-844-597-6373) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Link to US Package Insert including Boxed Warning.

HRA Pharma Rare Diseases, 200 avenue de Paris, 92320, Chatillon, FRANCE
Tel: +33 (0) 1 40 33 94 14 / Fax: +33 (0) 1 40 33 30 87
© 2021 HRA Pharma Rare Diseases | Lysodren is a registered trademark of HRA Pharma Rare Diseases
Privacy Policy | Cookies Policy
Last updated: June 2023; LYS – US – 0016

You are now leaving Lysodren.com

Lysodren.com provides links to web sites of other organizations. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Lysodren.com, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL

Lysodren